Allergan reported terrific top line growth, but the stock is cheap because the entire group is out of favor, said TheStreet’s (TST) Jim Cramer. He said the stock buyback will be accretive and puts a floor under the stock.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
